海王生物优化资本路径，聚焦核心战略轻装前行

Group 1 - The company has decided to terminate the control change plan and the A-share issuance plan after three years of planning, reflecting a proactive adjustment based on the current market environment and long-term development strategy [1] - The termination of the plans allows the management to focus on core business operations and strategic transformation, demonstrating a pragmatic attitude and strategic determination in response to market changes [1][3] - The company aims to concentrate resources on the high-growth potential medical device sector, having established a solid foundation in the medical device distribution field with a comprehensive supply chain network covering over 20 provinces and cities in China [2] Group 2 - The company has deepened strategic cooperation with top brands such as Siemens and Mindray Medical, laying a foundation for market expansion and service upgrades [2] - By actively divesting non-core assets and completing significant goodwill impairment, the company has effectively alleviated historical burdens, allowing for a focus on high-value areas [2] - The company achieved a revenue of 30.317 billion yuan in 2024, showcasing the resilience of its core business despite a challenging market environment [2] Group 3 - As a private enterprise, the company possesses natural advantages in decision-making efficiency, flexibility, and market sensitivity, which are reflected in its proactive adjustment of capital pathways [3] - The strategic focus on the medical device sector aligns with the industry's trend towards specialization, high value, and efficiency, providing the company with a broad space for future development [3] - The termination of the control change and capital increase plans marks a new phase in the company's strategic focus, laying a solid foundation for high-quality future development [3]